A controlled trial of idebenone in Huntington's disease

Neal G. Ranen, Carol E. Peyser, Joseph T. Coyle, Frederick W. Bylsma, Meeia Sherr, Leslie Day, Marshal F. Folstein, Jason Brandt, Christopher A. Ross, Susan E. Folstein

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

One hundred patients with clinically diagnosed Huntington's disease (HD) were randomized to either idebenone, an antioxidant and enhancer of oxidative metabolism, or placebo, in a 1-year, double-blind, parallel-group study aimed at slowing the rate of progression of the disease. Ninety-one patients completed the study. There were no significant differences between groups on the primary outcome measures of the Huntington's Disease Activities of Daily Living Scale (ADL - an index of functional status) and the Quantified Neurologic Examination (QNE). Sample size calculations based on progression of the ADL and QNE in this study group revealed that a larger study group is necessary to detect any differences less than an almost complete halting of the disease. This argues for multicenter efforts for future therapeutic trials in HD.

Original languageEnglish
Pages (from-to)549-554
Number of pages6
JournalMovement Disorders
Volume11
Issue number5
StatePublished - Sep 26 1996

Fingerprint

Huntington Disease
Activities of Daily Living
Neurologic Examination
Sample Size
Disease Progression
Antioxidants
Placebos
Outcome Assessment (Health Care)
idebenone
Therapeutics

Keywords

  • Antioxidants
  • Huntington's disease
  • Idebenone

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Ranen, N. G., Peyser, C. E., Coyle, J. T., Bylsma, F. W., Sherr, M., Day, L., ... Folstein, S. E. (1996). A controlled trial of idebenone in Huntington's disease. Movement Disorders, 11(5), 549-554.

A controlled trial of idebenone in Huntington's disease. / Ranen, Neal G.; Peyser, Carol E.; Coyle, Joseph T.; Bylsma, Frederick W.; Sherr, Meeia; Day, Leslie; Folstein, Marshal F.; Brandt, Jason; Ross, Christopher A.; Folstein, Susan E.

In: Movement Disorders, Vol. 11, No. 5, 26.09.1996, p. 549-554.

Research output: Contribution to journalArticle

Ranen, NG, Peyser, CE, Coyle, JT, Bylsma, FW, Sherr, M, Day, L, Folstein, MF, Brandt, J, Ross, CA & Folstein, SE 1996, 'A controlled trial of idebenone in Huntington's disease', Movement Disorders, vol. 11, no. 5, pp. 549-554.
Ranen NG, Peyser CE, Coyle JT, Bylsma FW, Sherr M, Day L et al. A controlled trial of idebenone in Huntington's disease. Movement Disorders. 1996 Sep 26;11(5):549-554.
Ranen, Neal G. ; Peyser, Carol E. ; Coyle, Joseph T. ; Bylsma, Frederick W. ; Sherr, Meeia ; Day, Leslie ; Folstein, Marshal F. ; Brandt, Jason ; Ross, Christopher A. ; Folstein, Susan E. / A controlled trial of idebenone in Huntington's disease. In: Movement Disorders. 1996 ; Vol. 11, No. 5. pp. 549-554.
@article{f9a0142b4ba64978b7165925eb041f98,
title = "A controlled trial of idebenone in Huntington's disease",
abstract = "One hundred patients with clinically diagnosed Huntington's disease (HD) were randomized to either idebenone, an antioxidant and enhancer of oxidative metabolism, or placebo, in a 1-year, double-blind, parallel-group study aimed at slowing the rate of progression of the disease. Ninety-one patients completed the study. There were no significant differences between groups on the primary outcome measures of the Huntington's Disease Activities of Daily Living Scale (ADL - an index of functional status) and the Quantified Neurologic Examination (QNE). Sample size calculations based on progression of the ADL and QNE in this study group revealed that a larger study group is necessary to detect any differences less than an almost complete halting of the disease. This argues for multicenter efforts for future therapeutic trials in HD.",
keywords = "Antioxidants, Huntington's disease, Idebenone",
author = "Ranen, {Neal G.} and Peyser, {Carol E.} and Coyle, {Joseph T.} and Bylsma, {Frederick W.} and Meeia Sherr and Leslie Day and Folstein, {Marshal F.} and Jason Brandt and Ross, {Christopher A.} and Folstein, {Susan E.}",
year = "1996",
month = "9",
day = "26",
language = "English",
volume = "11",
pages = "549--554",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - A controlled trial of idebenone in Huntington's disease

AU - Ranen, Neal G.

AU - Peyser, Carol E.

AU - Coyle, Joseph T.

AU - Bylsma, Frederick W.

AU - Sherr, Meeia

AU - Day, Leslie

AU - Folstein, Marshal F.

AU - Brandt, Jason

AU - Ross, Christopher A.

AU - Folstein, Susan E.

PY - 1996/9/26

Y1 - 1996/9/26

N2 - One hundred patients with clinically diagnosed Huntington's disease (HD) were randomized to either idebenone, an antioxidant and enhancer of oxidative metabolism, or placebo, in a 1-year, double-blind, parallel-group study aimed at slowing the rate of progression of the disease. Ninety-one patients completed the study. There were no significant differences between groups on the primary outcome measures of the Huntington's Disease Activities of Daily Living Scale (ADL - an index of functional status) and the Quantified Neurologic Examination (QNE). Sample size calculations based on progression of the ADL and QNE in this study group revealed that a larger study group is necessary to detect any differences less than an almost complete halting of the disease. This argues for multicenter efforts for future therapeutic trials in HD.

AB - One hundred patients with clinically diagnosed Huntington's disease (HD) were randomized to either idebenone, an antioxidant and enhancer of oxidative metabolism, or placebo, in a 1-year, double-blind, parallel-group study aimed at slowing the rate of progression of the disease. Ninety-one patients completed the study. There were no significant differences between groups on the primary outcome measures of the Huntington's Disease Activities of Daily Living Scale (ADL - an index of functional status) and the Quantified Neurologic Examination (QNE). Sample size calculations based on progression of the ADL and QNE in this study group revealed that a larger study group is necessary to detect any differences less than an almost complete halting of the disease. This argues for multicenter efforts for future therapeutic trials in HD.

KW - Antioxidants

KW - Huntington's disease

KW - Idebenone

UR - http://www.scopus.com/inward/record.url?scp=9544255791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9544255791&partnerID=8YFLogxK

M3 - Article

C2 - 8866496

AN - SCOPUS:9544255791

VL - 11

SP - 549

EP - 554

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 5

ER -